Mutational Analysis of TYR, OCA2, and SLC45A2 Genes in Chinese Families with Oculocutaneous Albinism

Ye Lin1* | Xihui Chen2* | Ying Yang3 | Fengyu Che3 | Sijia Zhang2 | Lijuan Yuan2,4† | Yuanming Wu2

1The General Hospital of the People’s Liberation Army, Beijing, P.R. China
2Department of Biochemistry and Molecular Biology, Center for DNA Typing, Air Force Medical University, Xi’an, Shaanxi, P.R. China
3Shaanxi Institute of Pediatric Diseases, Xi’an Children’s Hospital, Xi’an, Shaanxi, P.R. China
4Department of General Surgery, Tangdu Hospital, Air Force Medical University, Xi’an, Shaanxi, P.R. China

Correspondence
Yuanming Wu, Department of Biochemistry and Molecular Biology, Center for DNA Typing, Air Force Medical University, Xi’an, Shaanxi, P.R. China.
Email: wuym@fmmu.edu.cn

Funding information
the Key Project of the General Logistics Department, Grant/Award Number: AWS17J001; the key research and development plan in Shaanxi, Grant/Award Number: 2018SF-198; the Key Industrial Chain Project in Shaanxi, Grant/Award Number: 2016KTZDSF-01-03; National Natural Science Foundation of China, Grant/Award Number: 81502424 and 81671476

Abstract

Background: Oculocutaneous albinism (OCA) is a group of heterogeneous autosomal recessive genetic disorder of melanin synthesis results in hypopigmented hair, skin, and eyes. OCA type 1, OCA type 2, and OCA type 4, which are respectively caused by mutations in TYR, OCA2, and SLC45A2 have high morbidity rates in Asia.

Methods: TYR, OCA2, and SLC45A2 mutation analysis was carried out on 18 non-consanguineous OCA patients and four fetuses were included for prenatal diagnose. Three genes of all individuals were amplified by polymerase chain reaction and examined by Sanger sequencing. The pathogenicity of the detected mutations were analyzed by Mutation Taster, PolyPhen 2, and SIFT software, and the conservation of the substituted amino acids were analyzed by MEGA software.

Results: Eleven TYR mutations, three OCA2 mutations, and two SLC45A2 mutations were identified in 14 OCA type 1 patients, two OCA type 2 patients, and two OCA type 4 patients. c.1021A>G, p.R341G in TYR, c.1096_1104del, p.V366*, and c.1079C>T, p.S360F in OCA2 were novel. One of the four fetuses carried compound heterozygous mutation of TYR and became spontaneous abortion, the other three carried no mutations and appeared normal at birth.

Conclusion: In this study, specific clinical characteristics of OCA patients were described. Three novel pathogenic mutations were identified which will enrich the mutation spectrum of OCA, and the prenatal genetic screening in fetus at risk of OCA can provide vital information for genetic counseling.

KEYWORDS

OCA2, Oculocutaneous albinism, prenatal diagnosis, SLC45A2, TYR
1 | INTRODUCTION

Albinism is a heterogeneous genetic disorder of melanin synthesis. According to the patients’ pathological changes sites, it can be divided into ocular albinism (OA) and oculocutaneous albinism (OCA). OA patients have only hypopigmented eyes while OCA patients have a more widely affected area including hair, skin, and also associated with photophobia, nystagmus, strabismus, and variably reduced visual acuity. Syndromic OCA caused by mutations in HPS1, AP3B1, HPS3, HPS4, HPS5, HPS6, DTNBP1, BLOC1S3, PLDN, LYST, MYO5A, RAB27A, or MLPH can also combine with severe immune deficiency or platelet storage pool deficiency (Kamaraj & Purohit, 2014). While mutations in the TYR, OCA2, TYRP1, MATP (SLC45A2), SLC24A5, or C10orf11 can cause OCA type 1, OCA type 2, OCA type 3, OCA type 4, OCA type 6, and OCA type 7, respectively (Kamaraj et al., 2014), which are identified as nonsyndromic OCA.

Nonsyndromic OCA is a group of heterogeneous autosomal recessive disorders that affect one in 20,000 individuals worldwide, while the prevalence of the different subtypes of albinism varies considerably among the different ethnic backgrounds (Hutton & Spritz, 2008a; Rooryck et al., 2008). OCA type 1 is caused by homozygous or compound heterozygous mutations in TYR (OMIM #606933) located on chromosome 11q14. The protein it encodes is called tyrosinase, which is a copper-containing enzyme catalyzing the first two steps in melanin biosynthesis pathway required for melanin biosynthesis in the melanocytes of hair follicles, skin, and eyes (Cooksey et al., 1997). OCA type 1 is the most common subtype found in Caucasians and accounts for about 50% of OCA cases worldwide (Hutton & Spritz, 2008b). OCA type 2 also called brown OCA, is caused by mutations in OCA2 (also known as P gene, OMIM #611409) encoding a melanosome-specific transmembrane protein called P protein, which is required for melanin production by mediating a chloride-selective anion conductance (Bellono, Escobar, Lefkovith, Marks, & Oancea, 2014; Kamaraj et al., 2014; Passmore, Kaesmann-Kellner, & Weber, 1999). This type is most common in Africa and accounts for 30% of OCA cases worldwide (Okoro, 1975; Puri et al., 1997). OCA type 3, also known as rufous OCA, is mostly caused by the mutations in TYRP1 (OMIM #115,501). This gene encodes tyrosinase related protein 1 (Tyrp1) which is involved in the maintenance of melanosome structure and affects melanocyte proliferation and cell death (Fang, Tsuji, & Setaluri, 2002; Hirobe & Abe, 1999; Kobayashi, Imokawa, Bennett, & Hearing, 1998). Type 3 is hardly ever seen in Caucasians but affects almost 1/8,500 individuals in southern Africa and 3% of OCA cases worldwide (Rooryck et al., 2008). OCA type 4 is caused by mutations in the membrane-associated transporter protein gene (SLC45A2, previously known as MATP, OMIM #606202). The SLC45A2 protein expresses in melanocyte cell lines and plays a role as melanosome membrane-associated transporter (Fukamachi, Shimada, & Shima, 2001; Harada, Li, El-Gamil, Rosenberg, & Robbins, 2001). This type accounts for 17% of OCA cases worldwide and 25% in Japan (Inagaki et al., 2004; Rooryck et al., 2008). OCA type 5, type 6, and type 7 are three recently identified types of nonsyndromic OCA. Type 5 has been mapped to the human chromosome 4q24, which is a novel locus for nonsyndromic OCA (Kamaraj et al., 2014; Visser, Kayser, Grosveld, & Palstra, 2014), and type 6 and type 7 are respectively caused by mutations in SLC24A5 and C10orf11 (Wei et al., 2013). In Chinese Han population, comprehensive molecular analysis has revealed the spectral distribution of Chinese OCA: the three commonest types are OCA type 1, OCA type 2, and OCA type 4 with the prevalence of 64.3%, 11.7%, and 15.6%, respectively (Wei, Zang, Zhang, Yang, & Li, 2015).

Further research of albinism associated genes can help to develop molecular tools used for prenatal diagnosis of albinism. By far, prenatal screening of albinism by molecular analysis has been performed in Israeli families (Rosenmann et al., 2009), Taiwanese families (Hsieh et al., 2001), and Chinese families (Liu, Kong, Shi, Wu, & Jiang, 2014; Wei et al., 2015).

In this study, we performed mutational screening of TYR, OCA2, and SLC45A2 in 18 Chinese OCA patients, two novel mutations in OCA2 and one novel mutation in TYR were identified. Meanwhile, prenatal screening of TYR mutation was performed on four fetuses, which have provided important information for genetic counseling.

2 | PATIENTS AND METHODS

2.1 | Patients

Eighteen nonconsanguineous patients recruited from the DNA Genotype Center of the Air Force Medical University were clinically diagnosed as OCA according to the diagnostic criteria. Their symptoms included severely poor eyesight, refractive error and photophobia in eyes, and white or light-yellow skin or hair which did not change with ages (normal pigmentation in a Chinese population is black hair, black eye, and yellow skin), obvious syndromic forms of OCA were ruled out because no abnormalities of the immune system or symptoms in other organs were found. Written informed consent including genetic analysis and publication of personal photographs were obtained from the participants and this study was approved by the Medical Ethics Committee of the Air Force Military Medical University. A total of 21 families were screened, including 3 families receiving prenatal genetic counseling. Three common OCA related genes including TYR (NC_000011.10), OCA2 (NC_000015.10), and
SLC45A2 (NC_000005.10) were screened in the patients by Sanger sequencing. Given that OCA type 3 is seldom found in Asian patients, we did not test TYRPI in this study.

2.2 | Gene sequencing

Peripheral blood samples were collected from the patients and their parents for genomic DNA isolation using a DNA extraction kit (RelaxGene Blood DNA System, Tiangen Biotech, Beijing, China).

PCR primers were designed by Primer Premier 5.0 containing the sequences of all 5 exons of TYR (Table S1), 25 exons of OCA2 (Table S2), and 7 exons of SLC45A2 (Table S3) including all coding exons and the exon/intronic flanking regions (Tables S1–S3).

The 50 μl PCR reaction mixture contained 50–100 ng template DNA, 25 μl 2× Taq PCR MaterMix (Tiangen Biotech, Beijing, China), and 2 μl of each primer. PCR were carried out in the following steps: pre-denatured at 95°C for 3 min followed by 35 cycles of denaturation at 95°C for 30 s, annealing at 50–60°C (according to different primers) for 30 s to 1 min, then extension at 72°C for 40 s, followed by the final extension at 72°C for 10 min. All PCR product sizes were verified by electrophoresing in 1.5% agarose gel at 100 V for 30 min and staining by ethidium bromide.

The expected sizes of the amplified PCR products were sequenced by Big Dye Primer Cycle Sequencing kit and the ABI 310 Genetic Automated sequencer (Applied Biosystems, Foster city, CA, USA), according to the manufacturer’s instructions.

The sequencing results were then compared with the reference sequences of the TYR, OCA2, and SLC45A2 obtained from the Genome Bioinformatics Database of California Santa Cruz University and the suspected disease-related mutations were then verified by family co-segregation.

2.3 | Prenatal testing

Three of the fetal DNA samples were obtained by amniocentesis performed at the 17th week of gestation, and one was isolated from aborted fetal tissues when the spontaneous abortion happened at the ninth week of gestation. Genomic DNA was extracted using a micro DNA extraction kit (TIANamp Micro DNA Kit, Tiangen Biotech, Beijing, China). Then the DNA was amplified and sequenced as described above.

2.4 | In silico analysis of novel mutations

All the detected variations were assessed by the Albinism Databases (http://www.ifpcs.org/albinism/index.html), 1,000 Genomes Database (http://browser.1000genomes.org/index.html), gnomAD database (http://gnomad.broadinstitute.org/), and HGMD Professinal Database (http://portal.biobase-international.com/ghmd/pro/search_gene.php). The effects of novel mutations were further analyzed in silico. Mutation Taster (http://www.mutationtaster.org/), Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/), and SIFT (http://sift.jcvi.org/) were used to determine the pathogenicity of novel mutations. The protein stability changes upon novel mutations were assessed by I-Mutant2.0 (http://folding.biofold.org/cgi-bin/i-mutant2.0.cgi). The conservative analysis of single amino acid site was achieved by MEGA software and the conformation changes of polypeptide caused by amino acid substitutions were simulated by SWISS-MODEL (https://swissmodel.expasy.org).

3 | RESULTS

In our study, 18 OCA patients were definitely diagnosed through genetic testing. Fourteen patients were diagnosed as OCA type 1 due to the TYR mutations, two patients were affected by OCA2 mutations causing OCA type 2, another two patients were affected by SLC45A2 mutations causing OCA type 4. All patients had typical OCA symptoms on their skin, hair, and iris. Clinical features and mutation alleles of these 18 patients are shown in Table 1. Interestingly, one of the patients (Patient 15 in Table 1) with OCA2 mutations has white skin but a pigmented nevus at groin (Figure 1).

3.1 | Mutations identification

Gene analysis revealed 10 different TYR mutation alleles, one novel missense mutation c.1021A>G (p.R341G) in TYR was identified (Figure 2a). Among the 14 patients who were affected by TYR mutation, ten subjects were compound heterozygous, two subjects were homozygous (Patient 2 and 4 in Table 1) and two subjects were single heterozygous of mutant TYR alleles (Patient 13 and 14 in Table 1). Three TYR mutations accounted for 60.7% of all the mutations in TYR in this study. The most common mutation was c.929_930insC(p.R311Lfs*7) (Exon 2) accounting for 8/28 of the TYR mutation alleles, followed by c.832C>T(p.R278*) (Exon 2) accounting for 5/28 and c.896G>A(p.R299H) (Exon 2) accounting for 4/28. All other identified mutations occurred in only one or two subjects (Table 2).

Three mutation alleles were identified in two patients who were affected by OCA type 2. One of them (Patient 15 in Table 1) was heterozygous for two novel mutations that included one frameshift mutation (c.1096_1104del, P.V366*) and one missense mutation (c.1079C>T, p.S360F) (Figure 2b,c). Another one was homozygous for nonsense mutation (c.833T>G, p.L278*) which had been reported previously. (Table 4).

We also identified two mutation alleles in two patients affected by SLC45A2. One patient was compound
| Subject | Sex | Age (years) | Hair color | Skin color | Iris color | Molecular subtype | Causing gene | Exon | Subject genotype |
|---------|-----|-------------|------------|------------|------------|-------------------|--------------|------|-----------------|
| 1       | F   | 0.13        | White      | White      | Brown      | OCA1              | TYR          | 1/2  | c.832>C>T(p.R278*) c.346>C>T(p.R116*) |
| 2*      | M   | 40          | White      | White      | Gray       | OCA1              | TYR          | 2    | c.929_930insC(p.R311Lfs*7) c.929_930insC(p.R311Lfs*7) |
| 3       | M   | 0.01        | White      | White      | Unknown    | OCA1              | TYR          | 2    | c.896>G>A(p.R299H) c.929_930insC(p.R311Lfs*7) |
| 4*      | M   | 0.01        | White      | White      | Gray       | OCA1              | TYR          | 2    | c.929_930insC(p.R311Lfs*7) c.929_930insC(p.R311Lfs*7) |
| 5       | M   | 50          | White      | White      | Red-brown  | OCA1              | TYR          | 2    | c.929_930insC(p.R311Lfs*7) c.929_930insC(p.R311Lfs*7) |
| 6       | M   | 33          | White      | White      | Gray       | OCA1              | TYR          | 2/3  | c.896>G>A(p.R299H) c.1106>A>G(p.Y369C) |
| 7       | M   | 3           | Light-yellow | White     | Unknown    | OCA1              | TYR          | 2/4  | c.1199>G>T(p.W400L) c.895>C>T(p.R299C) |
| 8       | F   | 24          | White      | White      | Gray       | OCA1              | TYR          | 2    | c.929_930insC(p.R311Lfs*7) c.1021>A>G(p.R341G) |
| 9       | F   | 0.15        | White      | White      | Gray       | OCA1              | TYR          | 2    | c.929_930insC(p.R311Lfs*7) c.929_930insC(p.R311Lfs*7) |
| 10      | M   | 28          | White      | White      | Brown      | OCA1              | TYR          | 2    | c.929_930insC(p.R311Lfs*7) c.929_930insC(p.R311Lfs*7) |
| 11      | M   | 0.25        | White      | White      | Unknown    | OCA1              | TYR          | 1/4  | c.346>C>T(p.R116*) c.1199>G>T(p.W400L) |
| 12      | F   | 28          | White      | White      | Gray       | OCA1              | TYR          | 2    | c.929_930insC(p.R311Lfs*7) c.929_930insC(p.R311Lfs*7) |
| 13      | F   | 26          | White      | White      | Gray       | OCA1              | TYR          | 2    | c.929_930insC(p.R311Lfs*7) c.929_930insC(p.R311Lfs*7) |
| 14      | M   | 2           | White      | White      | Gray       | OCA1              | TYR          | 2/3  | c.929_930insC(p.R311Lfs*7) c.929_930insC(p.R311Lfs*7) |
| 15*     | F   | 0.01        | White      | White      | Unknown    | OCA2              | P            | 10   | c.1096_1104del(p.V366*) c.1079>C>T(p.S360F) |
| 16*     | F   | 0.17        | White      | White      | Brown      | OCA2              | P            | 8    | c.833>T>G(p.L278*) c.833>T>G(p.L278*) |
| 17      | F   | 0.06        | White      | White      | Gray       | OCA4              | SLC45A2      | 1/2  | c.328>G>A(p.G110R) c.478>G>C(p.D160H) |
| 18*     | M   | 0.17        | White      | White      | Gray       | OCA4              | SLC45A2      | 2    | c.478>G>C(p.D160H) c.478>G>C(p.D160H) |

**Note.** F, female; M, male.

The asterisk (*) means this patient was in homozygous form.

The pound sign (#) indicates the patient has a pigmented nevus.

The dash (─) in the genotype column means a putative uncharacterized allelic mutation that may not be in TYR or OCA2 and was not identified by the PCR primers used.

Novel mutations are in bold.
heterozygous for c.328G>A (p.G110R) in Exon 1 and c.478G>C (p.D160H) in Exon 2. The other was homozygous for c.478G>C (p.D160H). The mutations were missense mutation and had been previously reported.

3.2 | Prenatal genetic diagnosis

Four high‐risk fetuses were screened for TYR mutation according to their parental genotypes. Three of them did not carry any detectable mutation and none of these three subjects showed symptoms of OCA after birth. One fetus carried heterozygous mutant TYR alleles (Table 3). However, this fetus was spontaneously aborted for uncertain reason at the ninth week of gestation.

3.3 | In silico analysis and structural simulation of novel mutations

The three novel mutations, c.1021A>G (p.R341G), c.1079C>T (p.S360F), and c.1096_1104del (p.V366*), were all predicted as disease‐causing mutations by Mutation Taster, Polyphen and SIFT (Table 4). None of them was present in Albinism Databases, the 1,000 Genomes Database, gnomAD database, or the HGMD Professional Database. The R341 in TYR and S360 in P protein are highly conserved amino acids throughout evolution (Figure 3a). The R341G was assessed to decrease the TYR protein stability while S360F was predicted to increase the P protein stability by I‐Mutant2.0. Significant conformation changes of amino acid and polypeptide caused by the mutations can be observed through the simulation of SISWS‐MODEL (Figure 3b).

3.4 | Molecular pathology evaluation

According to the standards and guidelines for interpretation of sequence variants developed by the ACGM (Richards et al., 2015). Both of the c.1021A>G (p.R341G) and c.1079C>T, p.S360F mutations were evaluated as a pathogenic variant with one strong (PS2), two moderate (PM1, PM2), and four supporting (PP1, PP2, PP3, PP4) pathogenicity evidences. The pathogenicity of the deletion variant, c.1096_1104del (p.V366*) was determined as pathogenic by one very strong (PVS1) and one strong (PS2) pathogenicity evidences.
In this study, we performed mutation analysis of the TYR, OCA2, and SLC45A2 on 18 unrelated OCA patients and TYR analysis on four fetuses at risk for OCA. Mutations in TYR were the most frequent (77.8%) in this tested group, whereas mutations in OCA2 (11.1%) and SLC45A2 (11.1%) occurred more rarely than previously reported (Kamaraj et al., 2014; Khordadpoor-Deilamani, Akbari, Karimipoor, & Javadi, 2015).

A total of 28 OCA type 1 mutational alleles were found in this report (Table 2), including c.929_930insC in eight alleles, c.832C>T in five alleles, c.896G>A in four alleles, c.1199G>T and c.346C>T in two alleles, c.1021A>G, c.1106A>G, c.636A>T, c.71G>A, c.895C>T in one allele, respectively. Missense mutation (46.4%, 13/28) in our study was the most common mutation in OCA type 1 patients, which is consistent with the previous study (Ghodsinejad et al., 2014). The insertion mutation, c.929_930insC, located on TYR exon 2, was the most common mutation (28.6%, 8/28) TYR mutation (Table 2) in this study. This mutation has been reported to prevalent in Chinese OCA type 1 patients (Wang, Guo, Li, & Lian, 2009; Wei et al., 2010) and other east Asian countries such as Japanese and Korean (Goto et al., 2004; Park, Chae, Kim, & Kim, 2012; Suzuki & Tomita, 2008). The c.929_930insC frameshift results in a truncated tyrosinase polypeptide lacking one potential copper-binding region which will lead to completely lack of tyrosinase catalytic activity (Tomita, Takeda, Okinaga, Tagami, & Shibahara, 1989).

Another common TYR mutation in our study was c.832C>T(p.R278*) (17.9%, 5/28). This nonsense mutation results in the deamination of 5-methylcytosine at a CpG site (Tripathi et al., 1993) and the enzyme may completely inactivated for lacking one potential copper-binding region (Renugadevi, Sil, Perumalsamy, & Sundaresan, 2010). It was first reported in Indo-Pakistani patients (Tripathi et al., 1993).

Table 2: OCA1 mutational alleles detected in this study

| Gene   | Mutation type | Nucleotide change | Amino acid change | Exon No. | Mutation frequency |
|--------|---------------|-------------------|-------------------|----------|-------------------|
| TYR    | Missense      | c.1021A>G         | p.R341G           | Ex 2     | 1/28              |
|        |               | c.1106A>G         | p.Y369C           | Ex 3     | 1/28              |
|        |               | c.1199G>T         | p.W400L           | Ex 4     | 2/28              |
|        |               | c.636A>T          | p.R212S           | Ex 1     | 1/28              |
|        |               | c.71G>A           | p.C24Y            | Ex 1     | 1/28              |
|        |               | c.895C>T          | p.R299C           | Ex 2     | 1/28              |
|        |               | c.896G>A          | p.R299H           | Ex 2     | 4/28              |
|        | Nonsense      | c.832C>T          | p.R278*           | Ex 2     | 5/28              |
|        |               | c.346C>T          | p.R116*           | Ex 1     | 2/28              |
|        | Insertion     | c.929_930insC     | p.R311Lfs*7       | Ex 2     | 8/28              |
| OCA2   | Missense      | c.1079C>T         | p.S360F           | Ex 10    | 1/4               |
|        | Nonsense      | c.833T>G          | p.L278*           | Ex 8     | 2/4               |
|        | Deletion      | c.1096_1104del    | p.V366*           | Ex 10    | 1/4               |
| SLC45A2| Missense      | c.328G>A          | p.G110R           | Ex 1     | 1/4               |
|        |               | c.478G>C          | p.D160H           | Ex 2     | 3/4               |

Note: Novel mutations are in bold.
and then reported in various ethnic groups, such as European (King et al., 2003), Mexican (King et al., 2003), Jewish (Gershoni-Baruch et al., 1994; Goto et al., 2004), Indian (King et al., 2003), Japanese (Goto et al., 2004; Tomita & Miyamura, 1998), and Chinese (Wang et al., 2009). The frequency of the mutation was 17.9% in our study, which corresponds with a previous study in Chinese (18.8%) (Wang et al., 2009).

The third common mutation in TYR in our study was c.896G>A (p.R299H) (14.3%, 4/28) which is missense substitution in the central portion of tyrosinase. R299H missense mutation occurs within the so-called “CuA” region, which might be important for binding of atomic copper by these proteins. This mutation was first reported in Caucasian by Tripathi, Strunk, Giebel, Weleber, and Spritz (1992) and R299H substitution has been observed previously in Caucasian (Tripathi et al., 1992), Arab Christian (Gershoni-Baruch et al., 1994), Korean (Lee, Park, Lee, Lee, & Park, 1997), and Chinese (Wang et al., 2009) populations.

The two TYR mutations in our study, p.W400L and p.C24Y, have only been reported in Chinese OCA patients (Lin, Chien, Su, Lee, & Chen, 2006; Tsai et al., 1999; Wang et al., 2009), while p.R116*, p.Y369C, p.R212S, and p.R299C have also been described in Caucasian patients. Patient 8 was compound heterozygous for a known mutation (c.929_930insC, p.R311Lfs*7) and a novel mutation (c.1021A>G, p.R341G) in TYR. The p.R341G located in the copper B binding site of tyrosinase and might affect the protein function by impeding atomic copper binding.

Interestingly, Patient 15 was a 3-month-old girl with OCA type 2 who had a solitary pigmented nevus with a diameter of 3 mm in the right inguinal area. For the right inguinal area was a sun-protected area, the pigmented nevus was not a sun-related lesion. The genetic defect for OCA type 2 has been mapped to chromosome 15q11-q13. Individuals with OCA2 possess some degree of tyrosinase activity and therefore can produce melanin. This may explain the pigmented nevus that usually happens in OCA type 2 patients in this and other similar studies (Stevens, Ramsay, & Jenkins, 1997; van der Westhuizen, Beukes, Green, Sinclair, & Goedhals, 2015).

Moreover, we genotyped for four high-risk fetuses for mutations in TYR. The fetus which was spontaneous abortion...
at ninth week carried a single mutation allele of c.832C>T (p.R278*). The other three fetuses carried no TYR mutations, and showed no signs of OCA type 1 after birth. These data confirmed that prenatal genetic testing is possible for OCA disease prevention.

In conclusion, a total of 15 mutations were found in 18 Chinese OCA patients and four high-risk fetuses. Three novel mutations, c.1021A>G mutation in TYR, and the c.1096_1104del and c.1079C>T mutations in the OCA2, were first reported. All the novel mutations were assessed to be responsible for affecting the protein function and predicted to cause OCA. What’s more, the successful prenatal genetic tests for OCA helped to find out the reason of spontaneous abortion and will make a significant sense to reduce the burdens of the family and the society. These outcomes will expand the genotypic spectrum of OCA and highlight the importance of genetic counseling for families with OCA history or abortion history, and pave the way for more efficient carrier detection and genetic counseling.

### TABLE 4 Bioinformatic analysis results of the three novel mutations

| Novel mutation | Bioinformatic analysis |
|----------------|------------------------|
|                | Mutation Taster | Polyphen 2 | SIFT |
|                | Prediction | Score | Prediction | Score | Prediction | Score |
| p.R341G        | Disease causing | 0.999 | Probably damaging | 1.000 | Affect protein function | 0.01 |
| p.S360F        | Disease causing | 0.999 | Probably damaging | 0.998 | Affect protein function | 0.00 |
| c.1096_1104del | Disease causing | 1 | |

**FIGURE 3** (a) The R341 in TYR and S360 in P protein are highly conserved amino acids throughout evolution; (b) Simulation of the amino acids conformation changes by SISWS-MODEL.
ACKNOWLEDGMENTS

We sincerely appreciate all the participants in this project. This project is supported by National Natural Science Foundation of China (No. 81671476 and 81502424), the Key Industrial Chain Project in Shaanxi (No. 2016KTZDSF-01-03), and the Key Project of the General Logistics Department (No. AWS17J001).

CONFLICT OF INTEREST

None declared.

ORCID

Xihui Chen https://orcid.org/0000-0001-7115-9615

REFERENCES

Bellono, N. W., Escobar, I. E., Lefkovith, A. J., Marks, M. S., & Oancea, E. (2014). An intracellular anion channel critical for pigmentation. Elife, 3, e4543. https://doi.org/10.7554/eLife.04543.001

Cooksey, C. J., Garratt, P. J., Land, E. J., Pavel, S., Ramsden, C. A., Riley, P. A., & Smit, N. P. (1997). Evidence of the indirect formation of the catecholic intermediate substrate responsible for the autoactivation kinetics of tyrosinase. The Journal of Biological Chemistry, 272, 26226–26235. https://doi.org/10.1074/jbc.272.42.26226

Fang, D., Tsuji, Y., & Setaluri, V. (2002). Selective down-regulation of tyrosinase family gene TYRP1 by inhibition of the activity of melanocyte transcription factor, MITF. Nucleic Acids Research, 30, 3096–3106. https://doi.org/10.1093/nar/gkf424

Fukamachi, S., Shimada, A., & Shima, A. (2001). Mutations in the gene encoding B, a novel transporter protein, reduce melanin content in medaka. Nature Genetics, 28, 381–385. https://doi.org/10.1038/ng584

Gershoni-Baruch, R., Rosenmann, A., Droetto, S., Holmes, S., Tripathi, R. K., & Spritz, R. A. (1994). Mutations of the tyrosinase gene in patients with ocuocutaneous albinism from various ethnic groups in Israel. American Journal of Human Genetics, 54, 586–594.

Ghodsinejad Klahroudi, V., Kamalideghan, B., Arasteh Kani, A., Aryani, O., Tondar, M., Ahmadipour, F., … Houshmand, M. (2014). Two novel tyrosinase (TYR) gene mutations with pathogenic impact on ocucutaneous albinism type 1 (OCA1). PLoS ONE, 9, e106656. https://doi.org/10.1371/journal.pone.0106656

Goto, M., Sato-Matsumura, K. C., Sawamura, D., Yokota, K., Nakamura, H., & Shimizu, H. (2004). Tyrosinase gene analysis in Japanese patients with ocucutaneous albinism. Journal of Dermatological Science, 35, 215–220. https://doi.org/10.1016/j.jdermsci.2004.06.007

Harada, M., Li, Y. F., El-Gamil, M., Rosenberg, S. A., & Robbins, P. F. (2001). Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T cells. Cancer Research, 61, 1089–1094.

Hirobe, T., & Abe, H. (1999). Genetic and epigenetic control of the proliferation and differentiation of mouse epidermal melanocytes in culture. Pigment Cell Research, 12, 147–163. https://doi.org/10.1111/j.1600-0749.1999.tb00508.x

Hsieh, Y. Y., Wu, J. Y., Chang, C. C., Tsai, F. J., Lee, C. C., Tsai, H. D., & Tsai, C. H. (2001). Prenatal diagnosis of ocucutaneous albinism two mutations located at the same allele. Prenatal Diagnosis, 21, 200–201. https://doi.org/10.1002/1097-0223(200103)21:3<200::AID-PD31>3.0.CO;2-J

Hutton, S. M., & Spritz, R. A. (2008a). A comprehensive genetic study of autosomal recessive ocular albinism in Caucasian patients. Investigative Ophthalmology & Visual Science, 49, 868–872. https://doi.org/10.1167/iovs.07-0791

Hutton, S. M., & Spritz, R. A. (2008b). Comprehensive analysis of ocucutaneous albinism among non-Hispanic caucasians shows that OCA1 is the most prevalent OCA type. The Journal of Investigative Dermatology, 128, 2442–2450. https://doi.org/10.1038/jid.2008.109

Inagaki, K., Suzuki, T., Shimizu, H., Ishii, N., Umezawa, Y., Tada, J., … Tomita, Y. (2004). Oculocutaneous albinism type 4 is one of the most common types of albinism in Japan. American Journal of Human Genetics, 74, 466–471. https://doi.org/10.1086/382195

Kamaraj, B., & Purohit, R. (2014). Mutational analysis of ocucutaneous albinism: A compact review. Biomed Research International, https://doi.org/10.1155/2014/905472

Khordadpour-Deilamani, F., Akbari, M. T., Karimipoor, M., & Javadi, G. (2015). Sequence analysis of tyrosinase gene in ocular and ocucutaneous albinism patients: Introducing three novel mutations. Molecular Vision, 21, 730–735.

King, R. A., Pietsch, J., Fryer, J. P., Savage, S., Brott, M. J., Russell-Eggitt, I., … Oetting, W. S. (2003). Tyrosinase gene mutations in ocucutaneous albinism 1 (OCA1): Definition of the phenotype. Human Genetics, 113, 502–513. https://doi.org/10.1007/s00439-003-0998-1

Kobayashi, T., Imokawa, G., Bennett, D. C., & Hearing, V. J. (1998). Tyrosinase stabilization by Tyrp1 (the brown locus protein). The Journal of Biological Chemistry, 273, 31802–31806.

Lee, S. T., Park, S. K., Lee, H., Lee, J. S., & Park, Y. W. (1997). DNA-based prenatal diagnosis of a Korean family with tyrosinase-related ocucutaneous albinism (OCA1). The Japanese Journal of Human Genetics, 42, 499–505. https://doi.org/10.1007/BF02767026

Lin, S. Y., Chien, S. C., Su, Y. N., Lee, C. N., & Chen, C. P. (2006). Rapid genetic analysis of ocucutaneous albinism (OCA1) using denaturing high performance liquid chromatography (DHPLC) system. Prenatal Diagnosis, 26, 466–470. https://doi.org/10.1002/pd.1439

Liu, N., Kong, X. D., Shi, H. R., Wu, Q. H., & Jiang, M. (2014). Tyrosinase gene mutations in the Chinese Han population with OCA1. Genetics Research, 96, e14. https://doi.org/10.1017/S0016672314000160

Okoro, A. N. (1975). Albinism in Nigeria. A clinical and social study. British Journal of Dermatology, 92, 485–492.

Park, S. H., Chae, H., Kim, Y., & Kim, M. (2012). Molecular analysis of Korean patients with ocucutaneous albinism. Japanese Journal of Ophthalmology, 56, 98–103. https://doi.org/10.1007/s10384-011-0098-x

Passmore, L. A., Kaeasmann-Kellner, B., & Weber, B. H. (1999). Novel and recurrent mutations in the tyrosinase gene and the P gene in the German albino population. Human Genetics, 105, 200–210. https://doi.org/10.1007/s004390051090

Puri, N., Durbam-Pierre, D., Aquaron, R., Lund, P. M., King, R. A., & Brilliant, M. H. (1997). Type 2 ocucutaneous albinism (OCA2)
in Zimbabwe and Cameroon: Distribution of the 2.7-kb deletion allele of the P gene. *Human Genetics*, 100, 651–656. https://doi.org/10.1007/s004390050568

Renugadevi, K., Sil, A. K., Perumalsamy, V., & Sundaresan, P. (2010). Spectrum of candidate gene mutations associated with Indian familial oculocutaneous and ocular albinism. *Molecular Vision*, 16, 1514–1524.

Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., … Rehm, H. L. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genetics in Medicine*, 17, 405–424. https://doi.org/10.1038/gim.2015.30

Rooryck, C., Morice-Picard, F., Elcioglu, N. H., Lacombe, D., Taieb, A., & Arveiler, B. (2008). Molecular diagnosis of oculocutaneous albinism: New mutations in the OCA1–4 genes and practical aspects. *Pigment Cell Melanoma Research*, 21, 583–587. https://doi.org/10.1111/j.1755-148X.2008.00496.x

Rosenmann, A., Bejarano-Achache, I., Eli, D., Maftsir, G., Mizrahi-Meissonnier, L., & Blumenfeld, A. (2009). Prenatal molecular diagnosis of oculocutaneous albinism (OCA) in a large cohort of Israeli families. *Prenatal Diagnosis*, 29, 939–946. https://doi.org/10.1002/pd.2317

Suzuki, T., & Tomita, Y. (2008). Recent advances in genetic analyses of oculocutaneous albinism: New mutations in the OCA1–4 genes and practical aspects. *Pigment Cell & Melanoma Research*, 21, 1–9. https://doi.org/10.1016/j.jpigcr.2007.12.008

Toyonoku, K., Valencia, J. C., Kushimoto, T., Costin, G.-E., Virador, V. M., Vieira, W. D., … Hearing, V. J. (2002). The etiology of oculocutaneous albinism define two clusters of missense substitutions. *American Journal of Medical Genetics*, 43, 865–871. https://doi.org/10.1002/ajmg.1320430523

Tsai, C. H., Tsai, F. J., Wu, J. Y., Lin, S. P., Chang, J. G., Yang, C. F., & Lee, C. C. (1999). Insertion/deletion mutations of type I oculocutaneous albinism in Chinese patients from Taiwan. *Human Mutation*, 14, 542. https://doi.org/10.1002/(SICI)1098-1004(199912)14:6<542:AID-HUMU14>3.0.CO;2-3

Visser, M., Kayser, M., Grosveld, F., & Palstra, R. J. (2014). Genetic variation in regulatory DNA elements: The case of OCA2 transcriptional regulation. *Pigment Cell & Melanoma Research*, 27, 169–177. https://doi.org/10.1111 pcmr.12210

Wang, Y., Guo, X., Li, W., & Lian, S. (2009). Four novel mutations of TYR gene in Chinese OCA1 patients. *Journal of Dermatological Science*, 53, 80–81. https://doi.org/10.1016/j.jdermsci.2008.07.002

Wei, A., Wang, Y. u., Long, Y., Wang, Y. i., Guo, X., Zhou, Z., … Li, W. (2010). A comprehensive analysis reveals mutational spectra and common alleles in Chinese patients with oculocutaneous albinism. *The Journal of Investigative Dermatology*, 130, 716–724. https://doi.org/10.1038/jid.2009.339

Wei, A.-H., Zang, D.-J., Zhang, Z., Liu, X.-Z., He, X., Yang, L., … Li, W. (2013). Exome sequencing identifies SLC24A5 as a candidate gene for nonsyndromic oculocutaneous albinism. *Journal of Investigative Dermatology*, 133, 1834–1840. https://doi.org/10.1038/jid.2013.49

Wei, A. H., Zang, D. J., Zhang, Z., Yang, X. M., & Li, W. (2015). Prenatal genotyping of four common oculocutaneous albinism genes in 51 Chinese families. *Journal of Genetics and Genomics*, 42, 279–286. https://doi.org/10.1016/j.jgg.2015.05.001

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Lin Y, Chen X, Yang Y, et al. Mutational Analysis of TYR, OCA2, and SLC45A2 Genes in Chinese Families with Oculocutaneous Albinism. *Mol Genet Genomic Med*. 2019;7:e687. https://doi.org/10.1002/mgg3.687